Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drug

Documenti analoghi

• Preferences for Tapering Biologic Disease‐Modifying Antirheumatic Drugs Among People With Rheumatoid Arthritis: A Discrete Choice Experiment
  di: Suz Jack Chan, et al.
  Pubblicazione: (2024)
• Risk of Neuroinflammatory Diseases Among New Recipients of Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs
  di: Maximilian Casey, et al.
  Pubblicazione: (2024)
• Utilization of Biologic Disease‐Modifying Antirheumatic Therapy in Patients With Rheumatoid Arthritis and Recently Diagnosed Breast Cancer
  di: Juan I. Ruiz, et al.
  Pubblicazione: (2024)
• Pregnancy Outcomes of Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Among Patients With Autoimmune Diseases: A Scoping Review
  di: Vienna Cheng, et al.
  Pubblicazione: (2025)
• Sex Differences in Time to Initiate Nonsteroidal Anti‐Inflammatory Drugs or Biologic Disease‐Modifying Antirheumatic Drugs Among Patients With Axial Spondyloarthritis
  di: Divya Shridharmurthy, et al.
  Pubblicazione: (2024)